



ASX Announcement

10 October 2023

OPTISCAN ANNOUNCES KEY APPOINTMENTS FOR US OPERATION

Optiscan Imaging Limited (ASX: OIL) is pleased to advise a number of key leadership appointments as it pursues further growth and expansion of its subsidiary, **Optiscan Imaging, Inc.** in the United States.

The Company is delighted to announce that **Tim Rowe** and **Shayra Leon** have been appointed to the respective positions of **Business Development Manager (North America East Coast)** and **Business Development Manager (North America West Coast)**.

Mr Rowe joins Optiscan from Horiba Scientific Inc. where he was working as Regional Sales Manager for Fluorescence/Raman Spectroscopy/Custom Optical Spectroscopy, and previously as Senior Sales Engineer at PerkinElmer Health Sciences. Tim brings more than 15 years of experience in sales and business development in life sciences imaging to the Company. Commencing 10 October 2023, Mr. Rowe will initially be responsible for the growth of ViewnVivo® and the Company's life sciences business throughout the US and Canada with a focus on the East Coast.

Ms Leon joins Optiscan from Lumencor where she was working as Global Business Development Manager, and previously as a Sales Executive - Pathology at Leica Biosystems. Shayra brings more than 15 years of experience in sales and business development in pathology and imaging systems to the Company. Commencing 10 October 2023, Ms. Leon will initially be responsible for the growth of ViewnVivo® and the Company's life sciences business throughout the US and Canada with a focus on the West Coast.

Optiscan CEO and Managing Director Dr Camile Farah, stated, "These appointments reflect significant structuring and resourcing of our organisation in the US. Following an extensive search for exceptional talent, we are delighted to welcome Tim and Shayra to our team. Their experience will be extremely valuable as we strategically pursue the Company's commercial interests in the US. Their appointments signal the first stage of talent acquisition for our US operational structure, and we look forward to further expanding the team as our plans for US collaboration and commercialization continue."

Dr Camile Farah, continued, "The US market is strategically significant as we pursue recurring revenue generation. The inception of Optiscan Imaging Inc., a wholly owned subsidiary of the Company, and recruitment of high calibre personnel marks a new era of rapid growth and commercial success. I look forward to sharing further updates on key success and milestones in future."

P: (61 3) 9538 3333

A: 16 Miles St, Mulgrave VIC 3170, Australia

W: www.optiscan.com

Optiscan's Non-Executive Chairman, Mr Robert Cooke added, "The decision to implement a direct market business model underscores a significant and intricate undertaking by Dr. Farah and his team, which already encompasses jurisdictional responsibilities, taxation obligations and a commercial hub in Minnesota. The Board looks forward to supporting and furthering Dr. Farah's strategic vision for Optiscan Imaging Inc. in the United States."

This announcement has been authorised for release by the Board of Optiscan.

– ends –

For investor queries, please contact:

Dr. Camile Farah

Chief Executive Officer & Managing Director – Optiscan Imaging Ltd

E: cfarah@optiscan.com

About Optiscan

Optiscan Imaging Ltd (ASX:OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, *in-vivo* imaging at the single-cell level.

We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.

Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'future', 'intend', 'may', 'opportunity', 'plan', 'potential', 'project', 'seek', 'will' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.

P: (61 3) 9538 3333

A: 16 Miles St, Mulgrave VIC 3170, Australia

W: www.optiscan.com